Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer

Author

  • Thomas J. Hoffmann
  • Michael N. Passarelli
  • Rebecca E. Graff
  • Nima C. Emami
  • Lori C. Sakoda
  • Eric Jorgenson
  • Laurel A Habel
  • Jun Shan
  • Dilrini K. Ranatunga
  • Charles P. Quesenberry
  • Chun R. Chao
  • Nirupa R. Ghai
  • David Aaronson
  • Joseph Presti
  • Tobias Nordström
  • Zhaoming Wang
  • Sonja I Berndt
  • Stephen J Chanock
  • Jonathan D. Mosley
  • Robert J. Klein
  • Mridu Middha
  • Hans Lilja
  • Olle Melander
  • Mark N. Kvale
  • Pui Yan Kwok
  • Catherine Schaefer
  • Neil Risch
  • Stephen K Van Den Eeden
  • John S. Witte

Summary, in English

Prostate-specific antigen (PSA) levels have been used for detection and surveillance of prostate cancer (PCa). However, factors other than PCa - such as genetics - can impact PSA. Here we present findings from a genome-wide association study (GWAS) of PSA in 28,503 Kaiser Permanente whites and 17,428 men from replication cohorts. We detect 40 genome-wide significant (P<5 × 10-8) single-nucleotide polymorphisms (SNPs): 19 novel, 15 previously identified for PSA (14 of which were also PCa-associated), and 6 previously identified for PCa only. Further analysis incorporating PCa cases suggests that at least half of the 40 SNPs are PSA-associated independent of PCa. The 40 SNPs explain 9.5% of PSA variation in non-Hispanic whites, and the remaining GWAS SNPs explain an additional 31.7%; this percentage is higher in younger men, supporting the genetic basis of PSA levels. These findings provide important information about genetic markers for PSA that may improve PCa screening, thereby reducing over-diagnosis and over-treatment.

Department/s

  • Clinical Chemistry, Malmö
  • Cardiovascular Research - Hypertension
  • EpiHealth: Epidemiology for Health

Publishing year

2017-01-31

Language

English

Publication/Series

Nature Communications

Volume

8

Document type

Journal article

Publisher

Nature Publishing Group

Topic

  • Medical Genetics
  • Cancer and Oncology

Status

Published

Research group

  • Clinical Chemistry, Malmö
  • Cardiovascular Research - Hypertension

ISBN/ISSN/Other

  • ISSN: 2041-1723